HRP20211853T1 - Sastavi in situ injekcijskih biorazgradivih implantata - Google Patents
Sastavi in situ injekcijskih biorazgradivih implantata Download PDFInfo
- Publication number
- HRP20211853T1 HRP20211853T1 HRP20211853TT HRP20211853T HRP20211853T1 HR P20211853 T1 HRP20211853 T1 HR P20211853T1 HR P20211853T T HRP20211853T T HR P20211853TT HR P20211853 T HRP20211853 T HR P20211853T HR P20211853 T1 HRP20211853 T1 HR P20211853T1
- Authority
- HR
- Croatia
- Prior art keywords
- composition
- range
- polymer
- water
- drug
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 9
- 239000007943 implant Substances 0.000 title claims 2
- 238000011065 in-situ storage Methods 0.000 title claims 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 8
- 229920000642 polymer Polymers 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 5
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- 238000002347 injection Methods 0.000 claims 4
- 239000007924 injection Substances 0.000 claims 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims 4
- 229920000249 biocompatible polymer Polymers 0.000 claims 3
- 239000000243 solution Substances 0.000 claims 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000004310 lactic acid Substances 0.000 claims 2
- 235000014655 lactic acid Nutrition 0.000 claims 2
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 claims 2
- 239000000347 magnesium hydroxide Substances 0.000 claims 2
- 229910001862 magnesium hydroxide Inorganic materials 0.000 claims 2
- 235000012254 magnesium hydroxide Nutrition 0.000 claims 2
- 230000005855 radiation Effects 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 208000017667 Chronic Disease Diseases 0.000 claims 1
- 125000005907 alkyl ester group Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 229920001577 copolymer Polymers 0.000 claims 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 claims 1
- 229960002428 fentanyl Drugs 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims 1
- 229960003881 letrozole Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000178 monomer Substances 0.000 claims 1
- 229960005017 olanzapine Drugs 0.000 claims 1
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 claims 1
- 229960001534 risperidone Drugs 0.000 claims 1
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10382153.4A EP2394663B1 (en) | 2010-05-31 | 2010-05-31 | Compositions for injectable in-situ biodegradable implants |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20211853T1 true HRP20211853T1 (hr) | 2022-03-04 |
Family
ID=43301929
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211853TT HRP20211853T1 (hr) | 2010-05-31 | 2010-05-31 | Sastavi in situ injekcijskih biorazgradivih implantata |
| HRP20230890TT HRP20230890T1 (hr) | 2010-05-31 | 2011-05-31 | Metode za pripremu injektabilnih depo sastava |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20230890TT HRP20230890T1 (hr) | 2010-05-31 | 2011-05-31 | Metode za pripremu injektabilnih depo sastava |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US10058504B2 (https=) |
| EP (2) | EP2394663B1 (https=) |
| JP (1) | JP5923493B2 (https=) |
| CN (1) | CN102933234A (https=) |
| BR (1) | BR112012030707A2 (https=) |
| CA (1) | CA2800641C (https=) |
| CY (1) | CY1124783T1 (https=) |
| DK (1) | DK2582395T3 (https=) |
| EA (1) | EA024211B1 (https=) |
| ES (2) | ES2897976T3 (https=) |
| FI (1) | FI2582395T3 (https=) |
| HR (2) | HRP20211853T1 (https=) |
| HU (3) | HUE057236T2 (https=) |
| LT (2) | LT2394663T (https=) |
| MX (1) | MX346167B (https=) |
| PL (2) | PL2394663T3 (https=) |
| PT (2) | PT2394663T (https=) |
| RS (2) | RS64451B1 (https=) |
| SI (2) | SI2394663T1 (https=) |
| SM (2) | SMT202100679T1 (https=) |
| WO (1) | WO2011151356A2 (https=) |
| ZA (1) | ZA201209394B (https=) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8852638B2 (en) | 2005-09-30 | 2014-10-07 | Durect Corporation | Sustained release small molecule drug formulation |
| ES2562878T3 (es) | 2007-05-25 | 2016-03-08 | Indivior Uk Limited | Formulaciones de liberación sostenida de compuestos de risperidona |
| US10335366B2 (en) | 2010-05-31 | 2019-07-02 | Laboratorios Farmacéuticos Rovi, S.A. | Risperidone or paliperidone implant formulation |
| US10350159B2 (en) | 2010-05-31 | 2019-07-16 | Laboratories Farmacéuticos Rovi, S.A. | Paliperidone implant formulation |
| ES2390439B1 (es) * | 2012-08-03 | 2013-09-27 | Laboratorios Farmacéuticos Rovi, S.A. | Composición inyectable |
| US10285936B2 (en) | 2010-05-31 | 2019-05-14 | Laboratorios Farmacéuticos Rovi, S.A. | Injectable composition with aromatase inhibitor |
| US10881605B2 (en) | 2010-05-31 | 2021-01-05 | Laboratorios Farmaceuticos Rovi, S.A. | Methods for the preparation of injectable depot compositions |
| PL2394663T3 (pl) | 2010-05-31 | 2022-02-21 | Laboratorios Farmaceuticos Rovi, S.A. | Kompozycje do wstrzykiwania implantów biodegradowalnych in-situ |
| US10463607B2 (en) | 2010-05-31 | 2019-11-05 | Laboratorios Farmaceutics Rofi S.A. | Antipsychotic Injectable Depot Composition |
| PL2394664T3 (pl) | 2010-05-31 | 2016-12-30 | Preparat przeciwpsychotyczny do wstrzykiwań o przedłużonym uwalnianiu | |
| GB2513060B (en) | 2010-06-08 | 2015-01-07 | Rb Pharmaceuticals Ltd | Microparticle buprenorphine suspension |
| US9272044B2 (en) | 2010-06-08 | 2016-03-01 | Indivior Uk Limited | Injectable flowable composition buprenorphine |
| PT2529756T (pt) * | 2011-05-31 | 2021-07-28 | Farm Rovi Lab Sa | Formulação de implante de risperidona e/ou paliperidona |
| ES2456917T3 (es) * | 2011-05-31 | 2014-04-24 | Laboratorios Farmacéuticos Rovi, S.A. | Formulación de implante de paliperidona |
| US8935726B2 (en) | 2012-05-11 | 2015-01-13 | Comcast Cable Communications, Llc | Generation of dynamic content interfaces |
| EA033537B1 (ru) | 2013-03-11 | 2019-10-31 | Durect Corp | Инъекционная композиция с контролируемым высвобождением, содержащая жидкий носитель с высокой вязкостью |
| US20140308352A1 (en) | 2013-03-11 | 2014-10-16 | Zogenix Inc. | Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material |
| GB201404139D0 (en) | 2014-03-10 | 2014-04-23 | Rb Pharmaceuticals Ltd | Sustained release buprenorphine solution formulations |
| EP3352735B1 (en) | 2015-09-21 | 2023-08-30 | Teva Pharmaceuticals International GmbH | Sustained release olanzapine formulations |
| CN107811967B (zh) * | 2016-09-09 | 2021-08-24 | 中国疾病预防控制中心寄生虫病预防控制所(国家热带病研究中心) | 抗寄生虫药物原位固化缓释注射剂及其制备方法 |
| AU2017331340B2 (en) * | 2016-09-23 | 2023-09-28 | Delpor, Inc. | Compositions for small molecule therapeutic agent compounds |
| WO2018070940A1 (en) * | 2016-10-14 | 2018-04-19 | Nanyang Technological University | An injectable composition for localized controlled and sustained delivery system |
| DK3541442T3 (da) | 2016-11-16 | 2022-03-14 | Persica Pharmaceuticals Ltd | Antibiotiske formuleringer mod lændesmerter |
| WO2018172850A1 (en) | 2017-03-20 | 2018-09-27 | Teva Pharmaceuticals International Gmbh | Sustained release olanzapine formulaitons |
| DK3709970T3 (da) * | 2017-11-16 | 2025-07-07 | Persica Pharmaceuticals Ltd | Linezolidformuleringer |
| PE20210047A1 (es) | 2018-06-12 | 2021-01-08 | Farm Rovi Lab Sa | Composicion inyectable |
| US20240100012A1 (en) | 2021-01-18 | 2024-03-28 | Mark Hasleton | Pharmaceutical dosage form |
| JP2024529009A (ja) | 2021-07-06 | 2024-08-01 | マーク・ヘースルトン | セロトニン再取り込み阻害剤離脱症候群の治療 |
| US12318387B2 (en) | 2021-07-16 | 2025-06-03 | Laboratorios Farmaceuticos Rovi, S.A. | Method of treating acute exacerbation of schizophrenia with long-acting injectable depot composition |
| US12594236B2 (en) | 2021-07-16 | 2026-04-07 | Laboratorios Farmaceuticos Rovi, S.A. | Method of treating acute exacerbation of schizophrenia with long-acting injectable depot composition |
| TW202313047A (zh) | 2021-09-21 | 2023-04-01 | 西班牙商禾霏藥品實驗室有限公司 | 抗精神病可注射儲積型組合物 |
| CA3248062A1 (en) | 2022-05-18 | 2025-07-10 | Laboratorios Farmacéuticos Rovi, S.A. | Extended-release injectable compositions intended for use in treatment with risperidone in conjunction with CYP2D6 enzyme inhibitors |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| BE758156R (fr) | 1970-05-13 | 1971-04-28 | Ethicon Inc | Element de suture absorbable et sa |
| US4389330A (en) | 1980-10-06 | 1983-06-21 | Stolle Research And Development Corporation | Microencapsulation process |
| US4902506A (en) * | 1983-07-05 | 1990-02-20 | The University Of Rochester | Immunogenic conjugates |
| US4530840A (en) | 1982-07-29 | 1985-07-23 | The Stolle Research And Development Corporation | Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents |
| US4523591A (en) | 1982-10-22 | 1985-06-18 | Kaplan Donald S | Polymers for injection molding of absorbable surgical devices |
| US4938763B1 (en) | 1988-10-03 | 1995-07-04 | Atrix Lab Inc | Biodegradable in-situ forming implants and method of producing the same |
| US5620700A (en) | 1990-10-30 | 1997-04-15 | Alza Corporation | Injectable drug delivery system and method |
| US5656297A (en) * | 1992-03-12 | 1997-08-12 | Alkermes Controlled Therapeutics, Incorporated | Modulated release from biocompatible polymers |
| CN1074923C (zh) | 1993-11-19 | 2001-11-21 | 詹森药业有限公司 | 微囊密封的3-哌啶基取代的1,2-苯并异唑类和1,2-苯并异噻唑类 |
| US5620770A (en) | 1995-06-01 | 1997-04-15 | Superior Environmental Products, Inc. | Fifth wheel insert, laminate composite and method of construction |
| JP4642946B2 (ja) | 1996-12-20 | 2011-03-02 | アルザ コーポレイション | ゲル組成物および方法 |
| KR100289471B1 (ko) * | 1998-01-19 | 2001-09-17 | 김충섭 | 휀타닐계마취제의이식형서방성제제 |
| US6143314A (en) | 1998-10-28 | 2000-11-07 | Atrix Laboratories, Inc. | Controlled release liquid delivery compositions with low initial drug burst |
| US6565874B1 (en) | 1998-10-28 | 2003-05-20 | Atrix Laboratories | Polymeric delivery formulations of leuprolide with improved efficacy |
| US6461631B1 (en) | 1999-11-16 | 2002-10-08 | Atrix Laboratories, Inc. | Biodegradable polymer composition |
| ATE355824T1 (de) * | 2000-01-11 | 2007-03-15 | Roland Bodmeier | Kit zur implantation enthaltend eine trägerphase und ein lösungsmittel |
| US6604561B2 (en) * | 2000-02-11 | 2003-08-12 | Medical Instill Technologies, Inc. | Medicament vial having a heat-sealable cap, and apparatus and method for filling the vial |
| WO2002038185A2 (en) | 2000-11-13 | 2002-05-16 | Atrix Laboratories, Inc. | Injectable sustained release delivery system with loperamide |
| US6565080B1 (en) | 2001-12-17 | 2003-05-20 | Hewlett-Packard Development Company, L.P. | Imaging media loading guide |
| US7658998B2 (en) * | 2003-01-22 | 2010-02-09 | Alkermes Controlled Therapeutics, Inc. | Method of preparing sustained release microparticles |
| JP2007525429A (ja) | 2003-03-11 | 2007-09-06 | キューエルティー ユーエスエー，インコーポレイテッド． | 細胞スケジュール依存性抗癌剤のための処方 |
| US20050003007A1 (en) | 2003-07-02 | 2005-01-06 | Michele Boix | Method of sterilization of polymeric microparticles |
| ES2600554T3 (es) | 2003-07-18 | 2017-02-09 | Oakwood Laboratories L.L.C. | Prevención de la reducción del peso molecular del polímero, de la formación de impurezas y de la gelificación en composiciones poliméricas |
| US8444600B2 (en) * | 2003-09-17 | 2013-05-21 | Jae Sang Park | Replaceable heating cartridge for use with a warming device for medical treatment |
| US8221778B2 (en) | 2005-01-12 | 2012-07-17 | The Trustees Of The University Of Pennsylvania | Drug-containing implants and methods of use thereof |
| MX2007003789A (es) | 2004-10-04 | 2007-07-20 | Qlt Usa Inc | Suministro ocular de formulaciones polimericas para suministro. |
| US8313763B2 (en) | 2004-10-04 | 2012-11-20 | Tolmar Therapeutics, Inc. | Sustained delivery formulations of rapamycin compounds |
| RS53890B1 (sr) * | 2004-11-10 | 2015-08-31 | Tolmar Therapeutics, Inc. | Stabilizovan polimerni sistem za isporuku |
| DE102005031868A1 (de) * | 2005-07-04 | 2007-01-18 | Biotronik Vi Patent Ag | Arzneimitteldepot zur parenteralen, insbesondere intravaskulären Arzneimittelfreisetzung |
| US8852638B2 (en) | 2005-09-30 | 2014-10-07 | Durect Corporation | Sustained release small molecule drug formulation |
| SE0600876L (sv) * | 2006-04-20 | 2007-10-21 | Sandvik Intellectual Property | Verktyg och skär för spånavskiljande bearbetning med primära och sekundära ingreppsmedel med rotationssymmetrisk form |
| US8076448B2 (en) | 2006-10-11 | 2011-12-13 | Tolmar Therapeutics, Inc. | Preparation of biodegradable polyesters with low-burst properties by supercritical fluid extraction |
| PL2079767T3 (pl) * | 2006-10-11 | 2015-05-29 | Tolmar Therapeutics Inc | Wytwarzanie biodegradowalnych poliestrów z właściwościami niskiego wyrzutu przez ekstrakcję płynem nadkrytycznym |
| FR2908775B1 (fr) * | 2006-11-17 | 2012-08-31 | Biomatlante | Hydrogel et ses applications biomedicales |
| DK3660073T3 (da) | 2007-02-15 | 2023-09-18 | Tolmar International Ltd | Poly(lactid-co-glycolid) med lav sprængning |
| WO2008123456A1 (ja) * | 2007-03-29 | 2008-10-16 | Kyocera Corporation | 携帯無線機 |
| EP2167039B1 (en) * | 2007-05-18 | 2016-09-28 | Durect Corporation | Improved depot formulations |
| ES2562878T3 (es) | 2007-05-25 | 2016-03-08 | Indivior Uk Limited | Formulaciones de liberación sostenida de compuestos de risperidona |
| CL2008003305A1 (es) * | 2007-11-06 | 2009-06-05 | M/S Panacea Biotec Ltd | Composicion inyectable que comprende un agente activo seleccionado de un grupo definido; al menos un polimero bioerosionable, al menos un solvente no toxico y opcionalmente uno o mas excipientes; proceso de preparacion; uso para tratar enfermedades mentales o cancer. |
| US8629172B2 (en) * | 2008-04-18 | 2014-01-14 | Warsaw Orthopedic, Inc. | Methods and compositions for treating post-operative pain comprising clonidine |
| US10285936B2 (en) | 2010-05-31 | 2019-05-14 | Laboratorios Farmacéuticos Rovi, S.A. | Injectable composition with aromatase inhibitor |
| ES2390439B1 (es) | 2012-08-03 | 2013-09-27 | Laboratorios Farmacéuticos Rovi, S.A. | Composición inyectable |
| US10335366B2 (en) | 2010-05-31 | 2019-07-02 | Laboratorios Farmacéuticos Rovi, S.A. | Risperidone or paliperidone implant formulation |
| US10350159B2 (en) | 2010-05-31 | 2019-07-16 | Laboratories Farmacéuticos Rovi, S.A. | Paliperidone implant formulation |
| PL2394664T3 (pl) | 2010-05-31 | 2016-12-30 | Preparat przeciwpsychotyczny do wstrzykiwań o przedłużonym uwalnianiu | |
| PL2394663T3 (pl) | 2010-05-31 | 2022-02-21 | Laboratorios Farmaceuticos Rovi, S.A. | Kompozycje do wstrzykiwania implantów biodegradowalnych in-situ |
| PT2529756T (pt) | 2011-05-31 | 2021-07-28 | Farm Rovi Lab Sa | Formulação de implante de risperidona e/ou paliperidona |
| ES2456917T3 (es) | 2011-05-31 | 2014-04-24 | Laboratorios Farmacéuticos Rovi, S.A. | Formulación de implante de paliperidona |
-
2010
- 2010-05-31 PL PL10382153T patent/PL2394663T3/pl unknown
- 2010-05-31 EP EP10382153.4A patent/EP2394663B1/en active Active
- 2010-05-31 HR HRP20211853TT patent/HRP20211853T1/hr unknown
- 2010-05-31 ES ES10382153T patent/ES2897976T3/es active Active
- 2010-05-31 SI SI201032097T patent/SI2394663T1/sl unknown
- 2010-05-31 PT PT103821534T patent/PT2394663T/pt unknown
- 2010-05-31 SM SM20210679T patent/SMT202100679T1/it unknown
- 2010-05-31 LT LTEP10382153.4T patent/LT2394663T/lt unknown
- 2010-05-31 HU HUE10382153A patent/HUE057236T2/hu unknown
-
2011
- 2011-05-31 BR BR112012030707A patent/BR112012030707A2/pt not_active Application Discontinuation
- 2011-05-31 CN CN2011800265312A patent/CN102933234A/zh active Pending
- 2011-05-31 PT PT117234419T patent/PT2582395T/pt unknown
- 2011-05-31 EP EP11723441.9A patent/EP2582395B1/en active Active
- 2011-05-31 HU HUE11723441A patent/HUE063623T2/hu unknown
- 2011-05-31 FI FIEP11723441.9T patent/FI2582395T3/fi active
- 2011-05-31 JP JP2013512880A patent/JP5923493B2/ja active Active
- 2011-05-31 RS RS20230619A patent/RS64451B1/sr unknown
- 2011-05-31 MX MX2012013867A patent/MX346167B/es active IP Right Grant
- 2011-05-31 HR HRP20230890TT patent/HRP20230890T1/hr unknown
- 2011-05-31 SM SM20230241T patent/SMT202300241T1/it unknown
- 2011-05-31 SI SI201132088T patent/SI2582395T1/sl unknown
- 2011-05-31 CA CA2800641A patent/CA2800641C/en active Active
- 2011-05-31 PL PL11723441.9T patent/PL2582395T3/pl unknown
- 2011-05-31 EA EA201201570A patent/EA024211B1/ru unknown
- 2011-05-31 WO PCT/EP2011/059001 patent/WO2011151356A2/en not_active Ceased
- 2011-05-31 LT LTEPPCT/EP2011/059001T patent/LT2582395T/lt unknown
- 2011-05-31 ES ES11723441T patent/ES2950857T3/es active Active
- 2011-05-31 DK DK11723441.9T patent/DK2582395T3/da active
-
2012
- 2012-05-31 HU HUE12170362A patent/HUE054922T2/hu unknown
- 2012-05-31 RS RS20140075A patent/RS53205B/sr unknown
- 2012-11-30 US US13/690,707 patent/US10058504B2/en active Active
- 2012-12-11 ZA ZA2012/09394A patent/ZA201209394B/en unknown
-
2018
- 2018-07-11 US US16/032,270 patent/US10195138B2/en active Active
-
2021
- 2021-11-29 CY CY20211101041T patent/CY1124783T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20211853T1 (hr) | Sastavi in situ injekcijskih biorazgradivih implantata | |
| HRP20161049T1 (hr) | Sastav injektibilnog antipsihotika u depo obliku | |
| FI2854858T3 (fi) | Risperidoni-implanttivalmiste | |
| ES3015765T3 (en) | Pharmaceutical composition | |
| Kouchak | In situ gelling systems for drug delivery | |
| SI2648520T1 (en) | Dexmedetomidine premix formulation | |
| KR101871930B1 (ko) | 히알루론산 유도체를 이용한 온도감응성 유착방지용 하이드로겔 및 이의 제조방법 | |
| TW200803920A (en) | Sustained release small molecule drug formulation | |
| RU2011121612A (ru) | Инъекционная композиция полидезоксирибонуклеотидов для лечения костно-суставных заболеваний | |
| KR20160096205A (ko) | 메피바카인을 포함하는 히알루론산 조성물 | |
| RU2016139373A (ru) | Растворы бупренорфина с замедленным высвобождением | |
| HRP20200181T1 (hr) | Homogena vodena otopina hitozana pogodna za injekcije čiji je ph blizak fiziološkim ph | |
| SE536091C2 (sv) | Farmaceutisk komposition innehållande oxytocin eller fragment eller varianter därav och åtminstone en icke-jonisk cellulosaeter | |
| MX392770B (es) | Composición farmacéutica de estabilidad mejorada. | |
| HRP20220537T1 (hr) | Sastavi za ubrizgavanje koji sadrže letrozol ili anastrozol | |
| US10105387B2 (en) | Temperature sensitive adhesion prevention composition and use thereof | |
| Santoveña et al. | Structure-performance relationships of temperature-responsive PLGA-PEG-PLGA gels for sustained release of bone morphogenetic protein-2 | |
| CN112236142A (zh) | 用于缓释递送丁丙诺啡的药物组合物 | |
| HRP20150618T1 (hr) | Visokoelastiäśni gelovi pri operacijama oka | |
| Singh et al. | Design and development of sustained release injectable in situ gel of cytarabine | |
| CN101007171A (zh) | 家犬驱虫骨架型缓释植入剂及制备方法 | |
| CN104922085B (zh) | 一种利培酮植入剂及其制备方法 | |
| RU2008126108A (ru) | Фармацевтическая композиция для лечения остеоартрита, содержащая клодроновую кислоту и гиалуроновую кислоту | |
| Luciano De León | New treatments for Prosthetic Infections: Microparticles and personalised 3D printed Implants | |
| RU2438653C1 (ru) | Инъекционный растворитель пролонгированного действия для приготовления средств, применяемых при лечении гинекологических заболеваний в области онкологии |